在阿尔茨海默氏病的非典型临床病理形式中,更大程度上影响了coeruleus位置的脆弱性
Sara Rose Dunlop1, Billie J Matchett1, Alexander F Mannsbart1
1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 13, 2026
概括
在阿尔茨海默氏症 (AD) 中,心脏部位 (LC) 退化,在非典型的AD形式中损失更大. 这项研究量化了跨AD亚型的LC退化,揭示了不同的模式和预测因素.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 在阿尔茨海默氏症 (AD) 中,心脏部位 (LC) 经历了早期退化.
- 在各种AD临床病理学亚型中,LC退化的特定模式尚不清楚.
研究的目的:
- 为了调查阿尔茨海默氏病发病部内退化的程度和神经解剖学分布.
- 为了确定与AD中LC神经元损失相关的临床病理和人口因素.
主要方法:
- 利用数字病理学来量化神经元密度和神经元位置的面积.
- 在三个神经解剖学层面分析了大量的阿尔茨海默病病例.
主要成果:
- 与典型的和边缘主导的AD相比,海马节省的AD显示出更大的中间LC脆弱性.
- 发病时的年龄预测了罗斯特尔LC的神经密度,而布拉克阶段,大脑体重,勒维体病和发病时的年龄预测了中等LC的变异性.
- 非amnestic的AD病例表现出较低的罗斯特尔LC神经元密度比amnestic的病例.
结论:
- 在非典型的阿尔茨海默氏症呈现中,心脏部位退化更为明显.
- 研究结果突出显示,在海马节省AD,年轻发病AD和非amnesticAD形式中,LC的脆弱性更大.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Cerebral Edema ll: Pathophysiology
19
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
19
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


